These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28946642)

  • 1. E-Learning for Rare Diseases: An Example Using Fabry Disease.
    Cimmaruta C; Liguori L; Monticelli M; Andreotti G; Citro V
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28946642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabry-database.org: database of the clinical phenotypes, genotypes and mutant α-galactosidase A structures in Fabry disease.
    Saito S; Ohno K; Sakuraba H
    J Hum Genet; 2011 Jun; 56(6):467-8. PubMed ID: 21412250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones.
    Cammisa M; Correra A; Andreotti G; Cubellis MV
    Orphanet J Rare Dis; 2013 Jul; 8():111. PubMed ID: 23883437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fabry disease].
    Jakubowska E; Ryba M; Hruby Z
    Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mutation of α-galactosidase A gene causes Fabry disease mimicking primary erythromelalgia in a Chinese family.
    Ge W; Wei B; Zhu H; Miao Z; Zhang W; Leng C; Li J; Zhang D; Sun M; Xu X
    Int J Neurosci; 2017 May; 127(5):448-453. PubMed ID: 27211852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.
    Ashton-Prolla P; Tong B; Shabbeer J; Astrin KH; Eng CM; Desnick RJ
    J Investig Med; 2000 Jul; 48(4):227-35. PubMed ID: 10916280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
    Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
    Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genetics of Fabry disease: diagnostic and therapeutic implications].
    Germain DP
    Presse Med; 2007 Mar; 36 Spec No 1():1S14-9. PubMed ID: 17546762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-function relationships in alpha-galactosidase A.
    Garman SC
    Acta Paediatr; 2007 Apr; 96(455):6-16. PubMed ID: 17391432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular damage in Fabry disease: characterization and prediction of alpha-galactosidase A pathological mutations.
    Riera C; Lois S; Domínguez C; Fernandez-Cadenas I; Montaner J; Rodríguez-Sureda V; de la Cruz X
    Proteins; 2015 Jan; 83(1):91-104. PubMed ID: 25382311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
    Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
    Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel α-Galactosidase A Mutation (K391E) in a Young Woman With Severe Cardiac and Renal Manifestations of Fabry Disease.
    Wakakuri H; Nakamura S; Utsumi K; Shimizu W; Yasutake M
    Int Heart J; 2016 Sep; 57(5):637-9. PubMed ID: 27593536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A missense mutation, A156T, in the alpha-galactosidase A gene causes typical Fabry disease.
    Konoshita T; Mutoh H; Yokoi T; Koni I; Miyamori I; Mabuchi H
    Clin Nephrol; 2001 Mar; 55(3):243-7. PubMed ID: 11316246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two novel alpha-galactosidase A mutations causing Fabry disease: A missense mutation M11V in a heterozygote woman and a nonsense mutation R190X in a hemizygote man.
    Celtikci B; Topçu M; Ozkara HA
    Clin Biochem; 2011 Jul; 44(10-11):809-12. PubMed ID: 21569769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P.
    Fukutomi M; Tanaka N; Uchinoumi H; Kanemoto M; Nakao F; Yamada J; Kamei T; Takenaka T; Fujii T
    J Cardiol; 2013 Jul; 62(1):63-9. PubMed ID: 23608164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fabry disease: proposed guidelines from a French expert group for its diagnosis, treatment and follow-up].
    Lidove O; Bekri S; Goizet C; Khau Van Kien A; Aractingi S; Knebelmann B; Choukroun G; Tsimaratos M; Redonnet-Vernhet I; Lacombe D; Jaussaud R
    Presse Med; 2007; 36(7-8):1084-97. PubMed ID: 17276649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
    Duro G; Musumeci MB; Colomba P; Zizzo C; Albeggiani G; Mastromarino V; Volpe M; Autore C
    Gene; 2014 Feb; 535(2):365-9. PubMed ID: 24140492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene.
    Eng CM; Desnick RJ
    Hum Mutat; 1994; 3(2):103-11. PubMed ID: 7911050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel small insertion mutation, C.1030_1031ins (T) in α-galactosidase A leads to renal variant fabry disease.
    Choi JS; Kim CS; Park JW; Bae EH; Ma SK; Choi YD; Kim GH; Yoo HW; Kim SW
    Ren Fail; 2012; 34(3):390-3. PubMed ID: 22260214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.